Placental Cells for Diabetic Foot Ulcers
30. juni 2026 oppdatert av: Wake Forest University Health Sciences
Phase 1 Safety Trial of Placental Stem Cells (PLSC) to Accelerate the Healing of Diabetic Foot Ulcers
The purpose of this research study is to test the safety of placental stem cells to treat non-healing diabetic foot ulcers.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a prospective, non-randomized, single institution, Phase 1 safety trial to evaluate the safety of placental stem cells and the rate of diabetic foot ulcer healing in a population of subjects with non-healing diabetic foot ulcers for at least 4 weeks.
The trial will also explore the clinical outcomes of placental stem cells treatment on diabetic peripheral neuropathy.
Furthermore, the trial will evaluate the effect of the placental stem cells on serum biomarkers associated with diabetic foot ulcers and diabetic peripheral neuropathy (measured pre- and post-treatment) and correlate the biomarker levels with any changes in diabetic foot ulcers and diabetic peripheral neuropathy.
Twelve adult subjects with non-healing diabetic foot ulcers for at least four weeks from diagnosis and not more than 12 months with wound sizes ≥ 2 cm2 and ≤ 4 cm2 will be recruited and treated.
Subjects will be followed for 12 months after treatment.
Studietype
Intervensjonell
Registrering (Antatt)
12
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Mary-Clare Day, RN
- Telefonnummer: 336-713-1343
- E-post: maryclare.day@advocatehealth.org
Studiesteder
-
-
North Carolina
-
Winston-Salem, North Carolina, Forente stater, 27157
- Atrium Health Wake Forest Baptist
-
Ta kontakt med:
- Mary-Clare Day, RN
- Telefonnummer: 336-713-1343
- E-post: maryclare.day@advocatehealth.org
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Diagnosed with Type 2 Diabetes mellitus (DM) - for at least 1 year
- Unilateral non-healing Diabetic Foot Ulcer (DFU) > 2 cm2 and ≤ 4 cm2 (length × width) for at least four weeks despite Atrium Health Wake Forest Baptist standard of care treatment (which can include total contact cast, knee high air cast, and/or compression wrap)
- No new diabetes medication for at least 2 weeks pre-treatment
- Subjects must be willing to avoid steroids for the week prior to procedure day
Exclusion Criteria:
- Clinical signs of active infection requiring systemic antibiotic therapy less than 7 days prior to enrollment.
- Radiographic or clinical evidence of active and untreated osteomyelitis at the target ulcer site. Current use of systemic immunosuppressive therapy, including chronic corticosteroids (equivalent to >10 mg/day prednisone for >14 days).
- Hemoglobin (Hgb) A1C >12.0 at screening or time in range for the blood glucose level (TIR) less than 30%. Hb A1c should not be used for patient with hypoalbuminemia or anemia in the past 3 months and for patients with Chronic Kidney disease stage 4. For patients who have Continuous Glucose Monitor (CGM), instead of Hb A1c, TIR (time in range) less than 30 % will be used.
- Patients who are unable / unwilling to tolerate an effective offloading approach. This includes total contact cast, soft felted cast or knee high fracture boot.
- Current alcohol or substance abuse that, in the opinion of the investigators, would interfere with study participation.
- Active malignancy or malignancy related limb amputation.
- Women that are pregnant or planning to become pregnant during the study.
- Patients with albumin levels less than 3.5 or prealbumin levels less than 18.
- Subjects with any conditions that the clinical Investigator believes may jeopardize the safety of the patient to participate in the trial.
- Severe peripheral arterial disease (PAD) (Ankle-Brachial Index (ABI) less than 0.5) or TCOM (Transcutaneous Oximetry Measurement) less than 40 mmHg.
- TWSB > 30 cm2 (total wound surface burden)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Diabetic with Foot Ulcer
Type 2 diabetes mellitus with a non-healing (> 4 weeks) unilateral diabetic foot ulcer despite standard of care treatment
|
Injection of 30 M placenta stem cells into/around the diabetic foot ulcer and along the anterior and posterior tibial arteries of the index leg.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Injection Sites Bleeding
Tidsramme: Month 1
|
Number of Injection Sites Bleeding
|
Month 1
|
|
Number of Injection Sites Bleeding
Tidsramme: Month 3
|
Number of Injection Sites Bleeding
|
Month 3
|
|
Number of Injection Sites Bleeding
Tidsramme: Month 6
|
Number of Injection Sites Bleeding
|
Month 6
|
|
Number of Injection Sites Bleeding
Tidsramme: Month 12
|
Number of Injection Sites Bleeding
|
Month 12
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 1
|
Number of Injection Sites infection/inflammation
|
Month 1
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 3
|
Number of Injection Sites infection/inflammation
|
Month 3
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 6
|
Number of Injection Sites infection/inflammation
|
Month 6
|
|
Number of Injection Sites infection/inflammation
Tidsramme: Month 12
|
Number of Injection Sites infection/inflammation
|
Month 12
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 1
|
Number of Injection Sites with damage to surrounding tissue
|
Month 1
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 3
|
Number of Injection Sites with damage to surrounding tissue
|
Month 3
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 6
|
Number of Injection Sites with damage to surrounding tissue
|
Month 6
|
|
Number of Injection Sites with damage to surrounding tissue
Tidsramme: Month 12
|
Number of Injection Sites with damage to surrounding tissue
|
Month 12
|
|
Number of Subjects with pain
Tidsramme: Month 1
|
Number of Subjects with pain
|
Month 1
|
|
Number of Subjects with pain
Tidsramme: Month 3
|
Number of Subjects with pain
|
Month 3
|
|
Number of Subjects with pain
Tidsramme: Month 6
|
Number of Subjects with pain
|
Month 6
|
|
Number of Subjects with pain
Tidsramme: Month 12
|
Number of Subjects with pain
|
Month 12
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 1
|
Number of Subjects with allergic reaction to placental cells
|
Month 1
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 3
|
Number of Subjects with allergic reaction to placental cells
|
Month 3
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 6
|
Number of Subjects with allergic reaction to placental cells
|
Month 6
|
|
Number of Subjects with allergic reaction to placental cells
Tidsramme: Month 12
|
Number of Subjects with allergic reaction to placental cells
|
Month 12
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 1
|
Number of Subjects with worsening of wound
|
Month 1
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 3
|
Number of Subjects with worsening of wound
|
Month 3
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 6
|
Number of Subjects with worsening of wound
|
Month 6
|
|
Number of Subjects with worsening of wound
Tidsramme: Month 12
|
Number of Subjects with worsening of wound
|
Month 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Diabetic Foot Ulcer (DFU) size
Tidsramme: Month 12
|
DFU healing in this trial will be assessed by measuring the size of the DFU and plotting open wound size over the 12-month follow-up period.
|
Month 12
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Diabetic Peripheral Neuropathy - Semmes-Weinstein Monofilament and Vibration Test
Tidsramme: Months 1, 3, 6 and 12
|
The Semmes-Weinstein Monofilament Test is a diagnostic tool used to assess cutaneous touch and pressure sensation.
By using calibrated nylon strands that buckle at specific forces, clinicians can evaluate peripheral nerve function and reliably detect the loss of protective sensation, primarily caused by conditions like diabetic neuropathy
|
Months 1, 3, 6 and 12
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Lucian G. Vlad, MD, Atrium Health Wake Forest Baptist
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
1. oktober 2026
Primær fullføring (Antatt)
1. desember 2028
Studiet fullført (Antatt)
1. desember 2028
Datoer for studieregistrering
Først innsendt
30. juni 2026
Først innsendt som oppfylte QC-kriteriene
30. juni 2026
Først lagt ut (Faktiske)
7. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
7. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB00152562
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .